A new combo therapy for advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced and have spread (metastatic pancreatic cancer).
- You must not have received any previous cancer treatment.
- You must have at least one tumor that can be measured on scans.
- Your blood counts, liver, and kidney function must be within certain limits (the study doctor will check this).
- You cannot have other serious health conditions, like active infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new combination of an immunotherapy drug (QL1706) and two chemotherapy medicines (AG) as the first treatment for advanced pancreatic cancer. The goal is to see if the combination can shrink tumors and help patients live longer.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a new combination of two drugs (QL1706 and lenvatinib) for people whose esophageal cancer has progressed after initial immunotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
This trial tests a combination of two drugs, QL1706 and lenvatinib, in people with penile cancer that has already been treated with other therapies. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Hear when a new Advance Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.